Saturday, November 21, 2026
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Global Multiple Myeloma Burden Rises While Forecasts Predict Declining Future Rates

November 21, 2026
in Cancer
Nathaniel Bowman
By Nathaniel Bowman Scienmag Editorial Profile - Precision Oncology
Reading Time: 6 mins read
0
Global Multiple Myeloma Burden Rises While Forecasts Predict Declining Future Rates

Global Multiple Myeloma Burden Rises While Forecasts Predict Declining Future Rates

65
SHARES
587
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

A comprehensive epidemiological investigation utilizing the Global Burden of Disease 2021 database has tracked the shifting global impact of multiple myeloma over a thirty-year span, documenting significant upward trajectories in worldwide incidence, mortality, and overall disability between 1990 and 2021. Multiple myeloma, an incurable hematologic malignancy characterized by the uncontrolled proliferation of abnormal plasma cells within bone marrow, represents the second most prevalent blood cancer across the globe, accounting for approximately fourteen percent of newly diagnosed hematologic neoplasms. The global assessment calculated that in 2021 alone, the disease caused 148,755 incident cases, resulted in 116,359 deaths, and was responsible for 2,595,595 disability-adjusted life years worldwide. Across the full international evaluation, the age-standardized incidence rate was recorded at 1.74 cases per 100,000 population, the age-standardized mortality rate stood at 1.37 per 100,000 population, and the age-standardized rate for disability-adjusted life years reached 30.00 per 100,000 population, establishing baseline parameters that demonstrate how substantially the malignancy impacts modern public health systems.

To investigate the historical evolution of multiple myeloma and establish statistical trajectories across populations, researchers examined data spanning 204 countries and territories divided across 21 geographical regions and five Socio-Demographic Index classifications. The study applied segmented log-linear Joinpoint regression models alongside estimated annual percentage change metrics to trace trends across different healthcare environments. Over the analytical period extending from 1990 to 2021, the global age-standardized incidence rate for multiple myeloma experienced an average annual percentage change of 0.54 percent, corresponding to an absolute increase of 0.18 cases per 100,000 population. During this identical timeframe, the global age-standardized mortality rate and the age-standardized disability-adjusted life years rate each grew by an average annual percentage change of 0.20 percent and 0.18 percent, respectively, with both metrics recording an absolute increase of 0.06 cases per 100,000 population. These sustained increases highlight expanding clinical demands across regions where demographic shifts and expanding diagnostic capabilities have increasingly exposed the population to blood cancers.

The study uncovered pronounced geographic and socioeconomic divergence when stratifying disease metrics according to national development status and regional boundaries. High Socio-Demographic Index territories consistently demonstrated the most elevated baseline rates, registering an age-standardized incidence rate of 3.16 per 100,000, an age-standardized mortality rate of 2.28 per 100,000, and a disability-adjusted life years rate of 47.33 per 100,000 in 2021. Regionally, High-income Australasia exhibited the peak regional age-standardized incidence rate at 5.48 cases per 100,000 population, while Sweden documented the highest national incidence rate at 5.58 cases per 100,000 population. High-income North America experienced the highest regional mortality burden at 28.92 cases per 100,000 population, whereas the United Kingdom registered the highest national age-standardized mortality rate at 1.34 cases per 100,000 along with the peak national disability-adjusted life years rate of 71.30 per 100,000. In contrast, lower-income areas including Central Sub-Saharan Africa and Oceania reported the lowest statistical rates, reflecting stark contrasts in diagnostic infrastructure, registry completeness, and specialized oncology services.

While high-income countries maintained the greatest absolute rates of multiple myeloma, longitudinal trends revealed that the fastest acceleration in disease burden occurred within developing socioeconomic regions. Joinpoint regression demonstrated that Middle Socio-Demographic Index regions experienced the steepest growth in age-standardized incidence, logging an average annual percentage change of 2.34 percent between 1990 and 2021. This group also documented the most pronounced acceleration in age-standardized mortality, with an average annual percentage change of 1.91 percent, alongside an equivalent rise in disability-adjusted life years of 1.90 percent per year. At the national level, Georgia recorded the sharpest upward trend in both age-standardized incidence and mortality, displaying estimated annual percentage changes of 6.20 and 6.18, respectively. Meanwhile, Turkmenistan registered the highest national growth in disability-adjusted life years with an estimated annual percentage change of 6.04, highlighting how emerging healthcare systems face rapidly mounting clinical burdens as life expectancies rise without matching access to specialized myeloma care.

Demographic stratification within the Global Burden of Disease framework demonstrated consistent disparities across patient age groups and biological sexes. Throughout the entire study period, males consistently experienced a higher burden of multiple myeloma than females across every age bracket evaluated. In 2021, the highest age-standardized incidence and mortality rates were clustered within the 75 to 79 age cohort, whereas the highest age-standardized rate for disability-adjusted life years occurred among individuals aged 65 to 69. When examining broader age bands across historical tracking, populations aged 80 to 94 years maintained the highest overall rates and demonstrated sustained upward trends over time. Projections indicate that the disease will remain heavily concentrated among older individuals, with estimates indicating that seventy-seven percent of newly diagnosed multiple myeloma patients will be older than 65 years by 2035, emphasizing the clinical challenge of managing therapy toxicity and multi-agent treatment regimens in elderly populations.

The study specifically examined high body mass index as the primary modifiable risk factor formally recognized for multiple myeloma within the Global Burden of Disease framework. Attribution analysis revealed marked geographical heterogeneity in the proportion of myeloma burden linked directly to elevated body mass index, with the highest fractions concentrated in high-income regions. In High-income Australasia, Southern Latin America, and High-income North America, elevated body mass index accounted for 10.2 percent, 10.6 percent, and 11.0 percent of multiple myeloma deaths, respectively, and contributed 10.6 percent, 11.0 percent, and 11.5 percent to total regional disability-adjusted life years. Conversely, lower-income regions demonstrated substantially lower proportional burdens, with high body mass index accounting for 3.3 percent of deaths in South Asia, 4.0 percent in High-income Asia Pacific, and 4.1 percent in Southeast Asia, with corresponding disability fractions of 3.6 percent, 4.3 percent, and 4.4 percent, tracking closely with regional variations in obesity prevalence and dietary patterns.

To investigate whether the observed epidemiological associations between excess adiposity and multiple myeloma represented true causal relationships rather than observational confounding, the investigators executed a two-sample Mendelian randomization analysis. Genetic instruments were derived from genome-wide association studies comprising 224,849 cases and 456,426 controls of European ancestry for body mass index, paired with outcome summary statistics from the FinnGen database containing 585 multiple myeloma cases and 287,129 controls. Following rigorous quality control procedures that eliminated linkage disequilibrium and potential pleiotropic variants, 513 independent single-nucleotide polymorphisms were identified as valid instrumental variables, displaying robust F-statistics spanning from 28.6 to 1426.1. Utilizing the primary inverse-variance weighted estimation method, the analysis established that genetically predicted higher body mass index was positively associated with an increased risk of developing multiple myeloma, yielding an odds ratio of 1.14 with a ninety-five percent confidence interval of 0.79 to 1.69 and a significance value of P equals 0.04.

The validity of the causal Mendelian randomization estimate was supported through rigorous sensitivity and pleiotropy assessments that reinforced the primary findings. Cochran Q tests revealed no evidence of instrumental variable heterogeneity, recording a non-significant Q-test probability value of 0.99. Similarly, the MR-Egger regression intercept showed an absence of directional horizontal pleiotropy, with a probability value of 0.21. Leave-one-out sensitivity analyses verified that no individual single-nucleotide polymorphism disproportionately drove or skewed the overall causal estimate. Biologically, the authors noted that adipose tissue alterations linked to elevated body mass index downregulate key protective cytokines such as lipocalin, which has been shown in laboratory models to impede plasma cell proliferation and decrease tumor angiogenesis, alongside reductions in plasma adiponectin concentrations that are frequently documented in overweight and obese patient populations, providing plausible biological mechanisms linking obesity to myeloma progression.

Looking toward future clinical demands, the research team deployed Bayesian Age-Period-Cohort modeling based on Integrated Nested Laplace Approximations to project global epidemiological trends through the year 2035. The modeling forecasts a gradual decline in worldwide age-standardized rates across all three core metrics. By 2035, the global age-standardized incidence rate is projected to decrease to 1.64 cases per 100,000 population, with male incidence expected to reach 1.98 per 100,000 compared to 1.31 per 100,000 among females. The global age-standardized mortality rate is forecasted to decline to 2.07 cases per 100,000 population, remaining higher in men at 2.50 per 100,000 than in women at 1.67 per 100,000. Additionally, the global age-standardized rate for disability-adjusted life years is projected to decrease to 28.30 per 100,000 population, with males bearing a predicted rate of 33.22 per 100,000 versus 23.03 per 100,000 in females.

Despite the projected decreases in standardized rates driven by improved targeted treatments, CD38-directed immunotherapies, and expanded supportive care, the authors emphasized that absolute numbers of multiple myeloma cases will likely continue to rise due to global population growth and demographic aging. The study also highlighted methodological limitations, including historical heterogeneity in vital registration quality across low-income regions that likely caused an underestimation of true disease burden in resource-limited territories. Furthermore, the researchers noted that long-term forecasting models cannot fully anticipate sudden disruptions in diagnostic guidelines, healthcare funding, or novel pharmaceutical access. Consequently, health authorities are urged to pair obesity prevention initiatives in affluent nations with structural investments in diagnostic infrastructure and standardized oncology access across lower-income regions to counter the continuing global threat of multiple myeloma.

Subject of Research: Global burden, risk factors, and future projections of multiple myeloma

Article Title: Global burden of multiple myeloma(1990–2021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomization

Article References: Qu, R., Zhang, X., Zou, J., Ning, J., Zhao, Y., Liang, Y., & Zhang, Y. (2026). Global burden of multiple myeloma(1990–2021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomization. Journal of the Egyptian National Cancer Institute, 38(1), Article 44. https://doi.org/10.1186/s43046-026-00377-4

Image Credits: AI Generated

DOI: 10.1186/s43046-026-00377-4

Keywords: Multiple Myeloma, Global Burden of Disease, Epidemiology, Cancer Research, Mendelian Randomization, Body Mass Index, Public Health, Bayesian Forecasting, Hematologic Malignancy, Disease Burden, Disability-Adjusted Life Years, Cancer Mortality, Cancer Incidence, Health Disparities, Socio-Demographic Index, Global Oncology

Cite Scienmag News

Nathaniel Bowman. (November 21, 2026). Global Multiple Myeloma Burden Rises While Forecasts Predict Declining Future Rates. Scienmag. https://scienmag.com/global-multiple-myeloma-burden-rises-while-forecasts-predict-declining-future-rates/

Nathaniel Bowman. "Global Multiple Myeloma Burden Rises While Forecasts Predict Declining Future Rates." Scienmag, 21 November 2026, https://scienmag.com/global-multiple-myeloma-burden-rises-while-forecasts-predict-declining-future-rates/. Accessed 21 November 2026.

Nathaniel Bowman. "Global Multiple Myeloma Burden Rises While Forecasts Predict Declining Future Rates." Scienmag. November 21, 2026. https://scienmag.com/global-multiple-myeloma-burden-rises-while-forecasts-predict-declining-future-rates/

Tags: Bayesian Forecastingbody mass indexcancer incidencecancer mortalitycancer researchdisability-adjusted life yearsdisease burdenepidemiologyglobal burden of diseaseglobal oncologyHealth disparitieshematologic malignancyMendelian randomizationMultiple MyelomaPublic healthsocio-demographic index
Share26Tweet16
Previous Post

Generalized Camassa-Holm Solutions Lose Hölder Regularity Over Time in Besov Spaces

Next Post

Automated Sand Pluviation System Produces Uniform Deposits Using Constant Drop Height

Related Posts

Deep Learning Model Improves Bone Tumor Localization and Segmentation on Radiographs
Cancer

Deep Learning Model Improves Bone Tumor Localization and Segmentation on Radiographs

November 21, 2026
Silver-Loaded Nepeta glomerulosa Nanoemulsion Enhances Apoptosis in Lung and Gastric Cancer Cells
Cancer

Silver-Loaded Nepeta glomerulosa Nanoemulsion Enhances Apoptosis in Lung and Gastric Cancer Cells

November 21, 2026
Medullary Breast Tumors Link Strongly to BRCA1 Mutations in Literature Review
Cancer

Medullary Breast Tumors Link Strongly to BRCA1 Mutations in Literature Review

November 21, 2026
Spatial transcriptomics reveals pancreatic tumor differences in Black and non-Black patients
Cancer

Spatial transcriptomics reveals pancreatic tumor differences in Black and non-Black patients

November 21, 2026
Stiff Tumor Matrix Drives Exosome Formation and Release in Breast Cancer
Cancer

Stiff Tumor Matrix Drives Exosome Formation and Release in Breast Cancer

November 21, 2026
Kinshasa Study Links Socioeconomic Vulnerability and Stigma to Prolonged Cancer Care Delays
Cancer

Kinshasa Study Links Socioeconomic Vulnerability and Stigma to Prolonged Cancer Care Delays

November 21, 2026
Next Post
Automated Sand Pluviation System Produces Uniform Deposits Using Constant Drop Height

Automated Sand Pluviation System Produces Uniform Deposits Using Constant Drop Height

  • Mothers who receive childcare support from maternal grandparents show more optimized

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27656 shares
    Share 11059 Tweet 6912
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    1061 shares
    Share 424 Tweet 265
  • Bee body mass, pathogens and local climate influence heat tolerance

    682 shares
    Share 273 Tweet 171
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    546 shares
    Share 218 Tweet 137
  • Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function

    531 shares
    Share 212 Tweet 133
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Venetoclax-Rituximab Therapy Demonstrates High Effectiveness in Belgian Chronic Lymphocytic Leukemia Study
  • Kepler Optimized XGBoost Accurately Predicts Serrated Jointed Rock Shear Strength
  • Adapted Behavioural Therapy Shows Preliminary Feasibility and Safety in Bipolar Disorder Evaluation
  • Silicon Dioxide Particles Trigger Intestinal Cell Death Pathways in Mice

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Biotechnology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Editorial Policy
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Science News
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,151 other subscribers

© 2026 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2026 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading